MET and non-small cell lung carcinoma: After the use of the TKI gefitinib, 12 patients with advanced NSCLC were analyzed using capture-based targeted ultra-deep sequencing, revealing MET Y1248H and D1246N as acquired mutations in two patients, further confirming their resistance against type I MET-TKIs in silico, in vitro, and in vivo, which could be solved using TKIs type II, according to in vitro experiments’ results [61].